Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by insulin resistance and chronic hyperglycemia, which significantly increases the risk of cardiovascular diseases (CVD)[1,2] . Among the various complications associated with T2DM, left ventricular diastolic dysfunction (LVDD) has emerged as a common yet often overlooked condition [3]. It is characterized by impaired filling of the left ventricle during diastole, leading to heart failure with preserved ejection fraction (HFpEF), particularly prevalent among diabetic patients [4,5].
Non-Alcoholic Fatty Liver Disease (NAFLD) is increasingly recognized as a common co-morbidity in individuals with T2DM, affecting approximately 55.5% of this population [6]. The presence of NAFLD in T2DM patients has been linked to an exacerbation of cardiovascular risk factors, including hypertension, dyslipidemia, and systemic inflammation [7].
Emerging evidence suggests that NAFLD may independently contribute to the development of LVDD in patients with T2DM. Studies indicate that T2DM patients with NAFLD exhibit significant alterations in echocardiographic parameters compared to those without NAFLD [8–10]. A key indicator of diastolic function, where a lower E/A ratio suggests impaired relaxation of the left ventricle. Higher E/e' ratio indicates elevated left ventricular filling pressures, reflecting worsening diastolic function. An increase in Left Atrial Volume Index (LAVI) suggests chronic pressure overload due to diastolic dysfunction [11–13].These findings indicate that NAFLD may serve as a marker for increased risk of LVDD among T2DM patients, potentially leading to earlier detection and intervention strategies aimed at preventing heart failure.
This study aims to systematically compare the echocardiographic features indicative of LVDD between T2DM patients with and without NAFLD. By elucidating these differences, we can better understand the interplay between hepatic steatosis and cardiac dysfunction, ultimately informing clinical practices for managing cardiovascular risk in diabetic populations. Understanding the relationship between NAFLD and LVDD in T2DM is crucial for developing targeted interventions that can mitigate cardiovascular risks. Given the high prevalence of both conditions and their synergistic effects on cardiac health, this comparison will provide valuable insights into improving patient outcomes through early identification and management strategies tailored to this high-risk group.
Patients attending to the OPD as well as in-patients admitted to the Department of General Medicine of the hospitals with type 2 diabetes. A cross sectional study was conducted from May 2023 to October 2024. Patients aged >=18 years those willing to participate in the study and meeting the American diabetes association (ADA) criteria for diagnosis of diabetes mellitus were included for the study. Patients with a prior history of Ischemic Heart Disease (IHD), valvular disease, chronic heart failure, cirrhosis or overt nephropathy and those with known causes of chronic liver disease (i.e., alcohol or drug induced liver disease, hemochromatosis, or autoimmune or viral hepatitis) were excluded from the study. Following approval and clearance from the institutional ethics committee, patients meeting the inclusion criteria were enrolled in the study after providing informed written consent.
The diagnosis of diabetes mellitus was based on ADA guidelines. Non-alcoholic fatty liver disease (NAFLD) was clinically diagnosed as hepatic steatosis detected on ultrasound in the absence of alcohol consumption, viral hepatitis, drug-induced liver disease, iron overload, or other known causes of liver disease.
Body mass index (BMI) was calculated as weight (kg) divided by height (m²) and categorized as follows:
i. 18.5–22.9: Normal
ii. 23–24.9: Overweight
iii. ≥25: Obese (WHO-ASIAN criteria)
Waist circumference was measured midway between the lower rib margin and the superior anterior iliac crest. Blood pressure was measured on the right upper arm using a mercury sphygmomanometer with an appropriately sized cuff after the participant had been seated quietly for at least five minutes. Information on smoking and alcohol consumption was collected using a validated questionnaire. Standard two-dimensional echocardiography was utilized to evaluate cardiac structure and function. Measurements included left ventricular (LV) wall thickness, chamber dimensions, and mass in accordance with established echocardiographic protocols. Additionally, left ventricular end-diastolic and end-systolic volumes, along with resting ejection fraction (EF), were assessed. Each participant underwent liver ultrasound examination conducted by an experienced radiologist. Fatty liver infiltration was diagnosed based on characteristic sonographic findings, including increased echogenicity of the liver relative to the renal cortex, posterior beam attenuation, and reduced visualization of intrahepatic vessels and diaphragm contours. Hepatic steatosis was further graded semi-quantitatively into Grade 1 (mild), Grade 2 (moderate), and Grade 3 (severe) based on the extent of these features.
Statistical Analysis
Collected data were compiled in Microsoft Excel and analyzed using SPSS version 20. Descriptive statistics such as mean, median, standard deviation, interquartile range, and percentage were used for summarizing sociodemographic and clinical data. Categorical variables were compared using the Chi-square test. Continuous variables were evaluated using independent t-tests for normally distributed data and the Wilcoxon signed-rank test for non-parametric data. Additional statistical tests were applied as required based on data characteristics. A p-value less than 0.05 was considered statistically significant.
Results were visually represented using appropriate tables, charts, and graphs where necessary to aid interpretation.
Based on the study conducted by Hokyou lee et al[12], diastolic dysfunction in NAFLD and NON-NAFLD with type 2 diabetes mellitus were 59.7% and 49% assuming minimum expected difference between 2 groups to be 20% the sample size calculation was carried out using following formula
Where Zα/2=1.96
Z1-β=0.84
P1=59.7
P2=49.0
d=20
Therefore, the calculated sample size was 96 in each group. Hence the total sample size calculated in the current study was 192.
Sample size (n)= 200 was taken for the current study with each group containing 100.
To assess and compare left ventricular diastolic dysfunction (LVDD) in patients with type 2 diabetes mellitus (T2DM), with a focus on those with and without non-alcoholic fatty liver disease (NAFLD). A total of 200 patients who met the predefined inclusion and exclusion criteria were enrolled, with informed consent obtained before participation. Among the 200 patients included in the study, exactly half (n=100, 50%) had non-alcoholic fatty liver disease (NAFLD), while the remaining half did not (Table 1 and Figure 1). Among the 100 patients diagnosed with NAFLD, 39% exhibited hepatic steatosis Grade 1, while 61% had Grade 2. The predominance of Grade 2 steatosis suggests that a significant proportion of NAFLD patients had moderate to severe liver involvement. The age distribution was similar between the two groups, with the highest proportion of patients being over 70 years old (26%). The mean age was slightly lower in the NAFLD group (55.67 ± 15.32 years) compared to the non-NAFLD group (58.01 ± 15.10 years), but the difference was not statistically significant (p=0.28). This suggests that age was not a major differentiating factor between the two groups. The gender distribution was nearly equal in both groups, with 50% males and 50% females in the NAFLD group, compared to 47% males and 53% females in the non-NAFLD group (p=0.78).
Table 1 : Distribution of NAFLD and Non-NAFLD cases among patients
|
Variables |
No. of Patients (n=200) |
% |
|
NAFLD |
100 |
50 |
|
Non NAFLD |
100 |
50 |
Figure 1: Distribution of patients based on NAFLD and Non NAFLD
A significant majority (76%) of the total participants were classified as obese. Among those with NAFLD, 65% were obese, whereas 71% of those without NAFLD were obese. The mean BMI was 27.32 ± 4.94 kg/m² in the NAFLD group and 27.97 ± 4.73 kg/m² (Figure 2) in without NAFLD group (p=0.35), indicating no significant difference in BMI between the groups.
Figure 2: Distribution of BMI
Systolic blood pressure (SBP) was categorized into normal (<120 mmHg), pre-hypertensive (120-139 mmHg), and hypertensive (≥140 mmHg) groups. The distribution of hypertensive patients was nearly identical (26% in NAFLD vs. 25% in non-NAFLD), with no significant difference (p=0.14). This suggests that NAFLD is not independently associated with higher SBP in this cohort. Smoking habits were slightly more common in NAFLD patients (57%) compared to without NAFLD patients (51%), but this difference was not statistically significant (p=0.48). Diabetes duration was slightly longer in without NAFLD patients (mean: 11.69 ± 8.52 years) compared to NAFLD patients (mean: 10.61 ± 7.92 years), but this was not statistically significant (p=0.36). The proportion of patients with diabetic-range fasting blood sugar (FBS ≥126 mg/dL) was slightly higher in NAFLD patients (61%) than in non-NAFLD patients (55%), but the difference was not statistically significant (p=0.72). This indicates that fasting glucose levels were comparable between both groups. The mean HbA1c level was slightly lower in NAFLD patients (8.18 ± 2.14%) compared to non-NAFLD patients (8.79 ± 2.20%), but the p-value was 0.05 (Table 2), indicating borderline statistical significance. This suggests a potential but weak association between poorer glycemic control and absence of NAFLD.
Table 2 : Association of HbA1c with NAFLD and Non-NAFLD patients
|
HbA1c (%) |
Total(n=200) |
With NAFLD (n=100) |
Without NAFLD (n=100) |
P-value |
|
0-8.9 |
105 (52.5%) |
57 (57.0%) |
48 (48.0%) |
0.17 |
|
9.0-10.9 |
66 (33.0%) |
33 (33.0%) |
33 (33.0%) |
|
|
11-18 |
29 (14.5%) |
10 (10.0%) |
19 (19.0%) |
|
|
Mean ± SD |
8.49 ± 2.19 |
8.18 ± 2.14 |
8.79 ± 2.20 |
0.049 |
|
Median (Q1-Q3) |
8.80 (6.60-10.43) |
7.95 (6.28-10.10) |
9.25 (6.80-10.72) |
|
|
Min - Max |
4.50 - 12.00 |
4.70 - 11.90 |
4.50 - 12.00 |
*Significant if P value <0.05 (for chi square test and t- test)
LVEF was similar in both groups (59.00 ± 3.42% in NAFLD vs. 59.39 ± 2.74% in non-NAFLD, p=0.38), indicating no significant difference in systolic function (Table3). Diastolic dysfunction was significantly more prevalent in NAFLD patients (33%) compared to non-NAFLD patients (20%) (p=0.02). The proportion of patients with Grade 2 and Grade 3 LVDD was notably higher in NAFLD patients (24% and 3%, respectively) than in non-NAFLD patients (9% and 1%, respectively), indicating a strong association between NAFLD and LVDD severity (Table 4 &Figure 3).
Table 3: Comparison of LVEF between NAFLD and Non-NAFLD Cases
|
LVEF% |
Total(n=200) |
With NAFLD (n=100) |
Without NAFLD (n=100) |
P-value |
|
Mean ± SD |
59.20 ± 3.11 |
59.00 ± 3.42 |
59.39 ± 2.74 |
0.38 |
|
Median (Q1-Q3) |
60.00 (56.00-61.00) |
60.00 (56.00-61.00) |
60.00 (58.00-61.00) |
|
|
Min - Max |
50.00 - 65.00 |
50.00 - 65.00 |
50.00 - 64.00 |
*Significant if P value <0.05 (for T test)
Figure 3: Distribution of patients based on diastolic dysfunction
Table 4: Prevalence of Diastolic Dysfunction in NAFLD vs. Non-NAFLD Groups
|
Diastolic Dysfunction |
Total(n=200) |
With NAFLD (n=100) |
Without NAFLD (n=100) |
P-value |
|
Grade 1 |
16 (8.0%) |
6 (6.0%) |
10 (10.0%) |
0.02 |
|
Grade 2 |
33 (16.5%) |
24 (24.0%) |
9 (9.0%) |
|
|
Grade 3 |
4 (2.0%) |
3 (3.0%) |
1 (1.0%) |
|
|
None |
147 (73.5%) |
67 (67.0%) |
80 (80.0%) |
*Significant if P value <0.05 (for chi square test)
USG findings confirmed hepatic steatosis in 100% of NAFLD patients, with 39% having Grade 1 steatosis and 61% having Grade 2 steatosis (p<0.001). This reinforces the clinical diagnosis of NAFLD and highlights the importance of liver ultrasound in identifying hepatic involvement in T2DM patients (Table 5).
Table 5: Association of USG findings with NAFLD and Non-NAFLD
|
USG Abdomen |
Total(n=200) |
With NAFLD (n=100) |
Without NAFLD (n=100) |
P-value |
|
Normal |
100 (50%) |
0 (0%) |
100 (100 %) |
<0.001 |
|
Hepatic Steatosis Grade 1 |
39 (19.5%) |
39 (39%) |
0 (0%) |
|
|
Hepatic Steatosis Grade 2 |
61 (30.5%) |
61 (61%) |
0 (0%) |
TSH levels were comparable between the groups (2.92 ± 0.95 mIU/L in NAFLD vs. 3.08 ± 0.86 mIU/L in non-NAFLD, p=0.22), with no significant association between thyroid dysfunction and NAFLD.
Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are two highly prevalent metabolic disorders that frequently coexist and share common pathophysiological pathways [14]. Emerging evidence suggests that the presence of NAFLD in patients with T2DM significantly increases the risk of developing left ventricular diastolic dysfunction (LVDD), a precursor to heart failure with preserved ejection fraction (HFpEF) [15].
The coexistence of NAFLD and T2DM may exert synergistic effects on myocardial structure and function, potentially accelerating myocardial injury and contributing to the progression of diastolic dysfunction. Although the exact mechanisms are not fully understood, alterations in myocardial lipid metabolism, low-grade inflammation, and myocardial fibrosis have been proposed [16]. Given the silent and progressive nature of LVDD, early identification is crucial in high-risk populations like T2DM patients with NAFLD. Timely detection and intervention may prevent the progression to overt heart failure. Therefore, this cross-sectional study titled “Comparison of left ventricular diastolic dysfunction in type 2 diabetes mellitus patients with and without non-alcoholic fatty liver disease” was carried out for patients with type 2 diabetes.
The most striking observation from our study was the significantly higher prevalence of left ventricular diastolic dysfunction (LVDD) among type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD), observed in 33% of cases compared to 20% in those without NAFLD (p = 0.02). Additionally, patients with NAFLD exhibited more advanced grades of LVDD, with 24% showing Grade 2 and 3% exhibiting Grade 3 dysfunction, in contrast to only 9% and 1%, respectively, in the non-NAFLD group. These findings are consistent with prior research, notably by Mantovani et al [17]. Similarly, Bonapace et al [18] found a markedly higher prevalence of mild to moderate LVDD in patients with NAFLD compared to those without (71% vs. 33%; p < 0.001). Faramarzpour et al [19] further highlighted that 76.7% of diabetic patients had NAFLD and 81.1% had concurrent LVDD, though they did not find a statistically significant link between non-progressive NAFLD and LVDD. Supporting this, Wang et al [8] emphasized the association between NAFLD and increased LVDD risk in T2DM, suggesting that NAFLD could serve as a potential marker for early cardiac dysfunction in this population. The plausible mechanisms linking NAFLD and LVDD include systemic inflammation, insulin resistance, lipotoxicity, and myocardial fibrosis [20].
Among NAFLD patients, 61% had Grade 2 hepatic steatosis in the current study, indicating moderate to severe liver involvement. Higher grades of hepatic steatosis are closely associated with increased cardiac dysfunction, primarily driven by greater metabolic disturbances and elevated levels of inflammatory cytokines. Epidemiological evidence further supports a strong link between hepatic steatosis and an increased incidence of major adverse cardiovascular events (MACE) and subclinical cardiovascular disease, independent of traditional risk factors.
In the present study, both age and gender distributions were comparable between T2DM patients with and without NAFLD. Although the mean age was slightly lower among NAFLD patients (55.67 ± 15.32 years) compared to non-NAFLD patients (58.01 ± 15.10 years), the difference was not statistically significant (p=0.28). These findings are consistent with some previous research; for instance, a study in Singapore involving 436 T2DM patients found similar gender proportions in both NAFLD and non-NAFLD groups [21] . Several meta-analyses and cohort studies have reported a higher prevalence of NAFLD among women with T2DM, potentially linked to greater insulin resistance, dyslipidemia, and systemic inflammation in females. Conversely, population-based studies often report a higher overall prevalence of NAFLD in men [ 22], although this trend may shift within diabetic cohorts. These discrepancies may arise from differences in study populations, regional and ethnic backgrounds, age distributions, and underlying metabolic profiles. In conclusion, while the current study supports a lack of significant age or gender association with NAFLD in T2DM patients, broader evidence presents a mixed picture, highlighting the complexity and heterogeneity of NAFLD risk factors across populations.
In the current study, BMI and waist circumference (WC) did not differ significantly between the NAFLD and non-NAFLD groups (p=0.65 and p=0.59, respectively). Interestingly, obesity was slightly more common in the non-NAFLD group (65% vs. 70%), challenging the conventional view that BMI alone is a reliable predictor of NAFLD. This observation aligns with growing evidence that BMI by itself may be an inadequate marker for NAFLD, particularly in individuals who are metabolically unhealthy despite having normal weight [23].
In this study, systolic and diastolic blood pressures (SBP and DBP) were found to be nearly identical between patients with and without non-alcoholic fatty liver disease (NAFLD), and no statistically significant difference was observed in the prevalence of hypertension between the two groups. This finding, though seemingly at odds with broader epidemiological data, can be interpreted in light of several considerations. While a robust body of literature supports NAFLD as an independent risk factor for both prevalent and incident hypertension, largely through mechanisms involving insulin resistance, systemic inflammation, and endothelial dysfunction, such associations are not consistently observed across all populations or study designs [24-26].
With respect to smoking, the analysis revealed a slightly higher prevalence among NAFLD patients (57%) compared to those without NAFLD (51%), though this difference did not reach statistical significance. Smoking has been implicated in the pathogenesis of NAFLD in several large-scale studies, where both active and passive smoking have been associated with increased risk of hepatic steatosis, particularly in female populations [27,28].
The current study found that the duration of diabetes, fasting blood sugar (FBS), and postprandial blood sugar (PPBS) levels were similar between individuals with and without nonalcoholic fatty liver disease (NAFLD). Although PPBS levels were slightly higher in the NAFLD group, the difference was not statistically significant. Interestingly, glycated hemoglobin (HbA1c) was marginally lower among NAFLD patients, with borderline statistical significance. This finding suggests a weak or potentially inverse association between long-term glycemic control and NAFLD presence in this specific cohort. a recent study by Mawla Ali Sheikh et al.[29] from Bangladesh discovered that while NAFLD patients with diabetes had greater metabolic risk factors, differences in fasting insulin and other lipid markers were not always statistically significant between diabetic and non-diabetic NAFLD patients. While some previous studies align with these results, indicating that glycemic indices do not always differ significantly between diabetic patients with and without NAFLD, especially in populations with uniformly poor glycemic control, other research contradicts these findings. Several studies [30-32] have demonstrated that worsening glycemic parameters, including FBS, PPBS, and HbA1c, are associated with increasing severity of NAFLD. These discrepancies could be attributed to differences in study design, patient characteristics, or the use of antidiabetic medications with hepatic benefits, such as GLP-1 receptor agonists or SGLT2 inhibitors [33,34].
Meta-analyses by Xiang et al [35] have shown stronger associations between NAFLD and thyroid dysfunction in non-diabetic populations or when broader thyroid panels are evaluated, rather than TSH alone.
The confirmation of hepatic steatosis via ultrasound in all NAFLD patients in this study not only validates the clinical diagnosis but also underscores the practical value of ultrasound as a first-line screening tool for NAFLD in individuals with T2DM. The predominance of Grade 2 steatosis in the cohort further highlights the importance of early liver imaging in this high-risk population, especially given the well-documented association between steatosis severity and cardiovascular complications such as LVDD. These findings are in line with numerous studies that endorse ultrasound as a noninvasive, accessible, and cost-effective method with high sensitivity for detecting moderate-to-severe steatosis [36,37]. Although more advanced techniques like MRI-PDFF and CT offer greater precision, their cost, limited availability, and, in some cases, radiation exposure make them less practical for routine screening. Despite some limitations such as reduced sensitivity for mild steatosis and operator dependency ultrasound remains widely recommended for clinical use [38]. However, it cannot differentiate between simple steatosis and steatohepatitis (NASH) or accurately stage fibrosis, making liver biopsy or advanced imaging useful in select cases. Overall, these results support current clinical guidelines that advocate for routine liver imaging in T2DM patients to facilitate early detection of NAFLD and prevent potential cardiovascular and hepatic complications.
This study demonstrates a clear and statistically significant association between non-alcoholic fatty liver disease (NAFLD) and left ventricular diastolic dysfunction (LVDD) in patients with type 2 diabetes mellitus (T2DM). Despite comparable demographic, glycemic, lipid, blood pressure, and anthropometric profiles, patients with NAFLD exhibited a notably higher prevalence and severity of LVDD, suggesting an independent pathophysiological link. These findings reinforce the understanding of NAFLD as a multisystem disease with cardiovascular implications that extend beyond liver-related morbidity. Importantly, the presence of NAFLD appeared to contribute an additional and independent risk for subclinical cardiac dysfunction, even when traditional cardiovascular risk factors were accounted for. This underscores the need to recognize NAFLD as a critical component in the cardiovascular risk assessment of T2DM patients. Future longitudinal studies are warranted to determine whether reversing NAFLD can improve cardiac function and to identify biomarkers or imaging modalities for early detection of subclinical LVDD in this high-risk group.
LIMITATIONS:
This study’s cross-sectional design limits causal inference and prevents assessment of temporal relationships between NAFLD and LVDD. NAFLD was diagnosed using imaging rather than liver biopsy, which may underestimate disease severity and precludes histological characterization. Although traditional cardiovascular risk factors were adjusted for, residual confounding from unmeasured factors such as inflammation or insulin resistance cannot be excluded. Additionally, the single-center design and inclusion of only patients with T2DM may limit the generalizability of the findings.
No Conflicts of interest.
[1] De Rosa S, Arcidiacono B, Chiefari E, Brunetti A, Indolfi C, Foti DP. Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links. Front Endocrinol. 2018;9:2. doi:10.3389/fendo.2018.00002
[2] Kendall DM, Harmel AP. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance. Am J Manag Care. 2002;8(20 Suppl):S635-653; quiz S654-657.
[3] Cm W, Pillai G, Divakar A, Bhaskaran R. Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus: A Single-Centre Observational Study From a Tertiary Care Hospital in South India. Cureus. Published online February 6, 2023. doi:10.7759/cureus.34667
[4] Abudureyimu M, Luo X, Wang X, et al. Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. Jia WP, ed. Journal of Molecular Cell Biology. 2022;14(5):mjac028. doi:10.1093/jmcb/mjac028
[5] Ma C, Luo H, Fan L, Liu X, Gao C. Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis. Braz J Med Biol Res. 2020;53(7):e9646. doi:10.1590/1414-431x20209646.
[6] Kosmalski M, ?liwi?ska A, Drzewoski J. Non-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus—The Chicken or the Egg Dilemma. Biomedicines. 2023;11(4):1097. doi:10.3390/biomedicines11041097
[7] Caussy C, Aubin A, Loomba R. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Curr Diab Rep. 2021;21(5):15. doi:10.1007/s11892-021-01383-7.
[8] Wang S, Zhang X, Zhang Q, Zhang B, Zhao L. Is non-alcoholic fatty liver disease a sign of left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus? A systematic review and meta-analysis. BMJ Open Diab Res Care. 2023;11(1):e003198. doi:10.1136/bmjdrc-2022-003198
[9] Mantovani A, Marchesi F, Porta C, Sica A, Allavena P. Inflammation and cancer: Breast cancer as a prototype. The Breast. 2007;16:27-33. doi:10.1016/j.breast.2007.07.013
[10] Sheba W, Morsy E, Altahan S, Ayaad M, Lashen SA. Nonalcoholic fatty liver disease is associated with early left ventricular diastolic dysfunction in patients with type 2 diabeteS. Alexandria Journal of Medicine. 2022;58(1):117-124. doi:10.1080/20905068.2022.2132603.
[11] Goliopoulou A, Theofilis P, Oikonomou E, et al. Non-Alcoholic Fatty Liver Disease and Echocardiographic Parameters of Left Ventricular Diastolic Function: A Systematic Review and Meta-Analysis. IJMS. 2023;24(18):14292. doi:10.3390/ijms241814292
[12] Lee H, Kim G, Choi YJ, et al. Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus. Diabetes Metab J. 2020;44(2):267. doi:10.4093/dmj.2019.0001
[13] Cassidy S, Hallsworth K, Thoma C, et al. Cardiac structure and function are altered in type 2 diabetes and Non-alcoholic fatty liver disease and associate with glycemic control. Cardiovasc Diabetol. 2015;14(1):23. doi:10.1186/s12933-015-0187-2.
[14] Dharmalingam M, Yamasandhi Pg. Nonalcoholic fatty liver disease and Type 2 diabetes mellitus. Indian J Endocr Metab. 2018;22(3):421.
[15] Wijarnpreecha K, Lou S, Panjawatanan P, et al. Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis. Digestive and Liver Disease. 2018;50(11):1166-1175.
[16] Peng D, Yu Z, Wang M, et al. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology. Front Endocrinol. 2022;13:935390.
[17] Mantovani A, Pernigo M, Bergamini C, et al. Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes. Chen X, ed. PLoS ONE. 2015;10(8):e0135329.
[17] Bonapace S, Perseghin G, Molon G, et al. Nonalcoholic Fatty Liver Disease Is Associated With Left Ventricular Diastolic Dysfunction in Patients With Type 2 Diabetes. Diabetes Care. 2012;35(2):389-395.
[18] Faramarzpour M, Mohammad Hosseiniazar M, Hooshmand Gharabagh L. Assessment of Relationship between Non-alcoholic Fatty Liver Disease and LV Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus. Caspian J Intern Med. 2025;16(1).
[19] Lee J, Shin MS. Nonalcoholic fatty liver disease and heart failure with preserved ejection fraction: a focus on risk factors and management. CPP. 2025;7(1):1-8.
[20] Chen K, Sng WK, Quah JHM, et al. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus. Yu ML, ed. PLoS ONE. 2020;15(8):e0236977.
[21] Sinha A, Bankura B. Prevalence of nonalcoholic fatty liver disease in type 2 diabetes mellitus patients from the Eastern region of India. Diabetes Epidemiology and Management. 2023;12:100161.
[22] DiStefano JK, Gerhard GS. NAFLD in normal weight individuals. Diabetol Metab Syndr. 2022;14(1):45.
[23] Friebel R, Molloy A, Leatherman S, Dixon J, Bauhoff S, Chalkidou K. Achieving high-quality universal health coverage: a perspective from the National Health Service in England. BMJ Glob Health. 2018;3(6):e000944.
[24] Jichitu A, Bungau S, Stanescu AMA, et al. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics. 2021;11(4):689.
[25] Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Molecular Metabolism. 2020; 42:101092.
[26] Ge X, Lu J, Yu C, et al. Associations Between Active, Passive Smoking and the Risk of Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2024;12(1):113-118.
[27] He X, Zhang S, Bai Q, et al. Air pollution exposure and prevalence of non-alcoholic fatty liver disease and related cirrhosis: A systematic review and meta-analysis. Ecotoxicology and Environmental Safety. 2025;289:117469.
[28] Mawla Ali Sheikh Md, Anisur Rahman Md, Mahmud Bhuiyan T, Golam Azam Md. Anthropometric and Biochemical Findings in Non-Alcoholic Fatty Liver Disease with or Without Diabetes. IJG.
[29] Miyake T, Furukawa S, Matsuura B, et al. Glycemic Control Is Associated with Histological Findings of Nonalcoholic Fatty Liver Disease. Diabetes Metab J. 2024;48(3):440-448.
[30] Anjum S, A T, C.P N, et al. Association of non-alcoholic fatty liver disease (NAFLD) and insulin resistance in type 2diabetes. rjms. 2020;10(1):151.
[31] Xie Y, Kong W, Wang X, Wu Z. Association of glycated hemoglobin with non-alcoholic fatty liver disease patients and the severity of liver steatosis and fibrosis measured by transient elastography in adults without diabetes. BMC Endocr Disord. 2022;22(1):220.
[32] Chang KC, Kuo FC, Yang CY, Yang CT, Ou HT, Kuo S. Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case–control study. Cardiovasc Diabetol. 2024;23(1):367
[33] Alexopoulos A, Crowley MJ, Wang Y, et al. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. Hepatology. 2021;74(3):1220-1233.
[34] Xiang L lan, Cao Y tian, Sun J, et al. Association between thyroid function and nonalcoholic fatty liver disease: a dose-response meta-analysis. Front Endocrinol. 2024;15:1399517.
[35] Bozic D, Podrug K, Mikolasevic I, Grgurevic I. Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal. Diagnostics. 2022;12(10):2287.
[36] Li G, Zhang X, Lin H, Liang LY, Wong GLH, Wong VWS. Non-invasive tests of non-alcoholic fatty liver disease. Chinese Medical Journal. 2022;135(05):532-546.
[37] Kc D, Misra R, Bagri N, Aggarwal A, Kampani G. Diagnostic Performance of Ultrasound in Detecting Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease Considering MRI Proton Density Fat Fraction as the Reference Standard. Journal of Global Radiology. 2024;10(1).
[38] Nelson SM, Hoskins JD, Lisanti C, Chaudhuri J. Ultrasound Fatty Liver Indicator: A Simple Tool for Differentiating Steatosis From Nonalcoholic Steatohepatitis: Validity in the Average Obese Population. J of Ultrasound Medicine. 2020;39(4):749-759.
IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications